Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

V R Adams

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Pharmacotherapy|July 25, 2000
Adverse events associated with chemotherapy for common cancersV R Adams
Journal of the American Pharmaceutical Association (Washington, D.C. : 1996)|October 26, 1999
Oprelvekin (Neumega), first platelet growth factor for thrombocytopeniaV R Adams, T Brenner
The Annals of Pharmacotherapy|December 1, 1995
Granisetron: the second serotonin-receptor antagonistV R Adams, A W Valley
Journal of the American Pharmaceutical Association (Washington, D.C. : 1996)|February 28, 1998
Cancer vaccines (1)P A Hallin, V R Adams
Journal of the American Pharmaceutical Association (Washington, D.C. : 1996)|January 13, 1998
Cancer vaccines. Part 2P A Hallin, V R Adams
The Annals of Pharmacotherapy|October 31, 2000
Computerized system for outcomes-based antiemetic therapy in childrenM T Holdsworth, V R Adams, D W Raisch, et al.
The Annals of Pharmacotherapy|January 1, 1995
Continuous midazolam infusion for the management of morphine-induced myoclonusM T Holdsworth, V R Adams, C M Chavez, et al.
Transplantation|February 11, 1998
Delayed graft function after renal transplantationW W Pfaff, R J Howard, P R Patton, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 19, 2004
Amifostine and autologous hematopoietic stem cell support of escalating-dose melphalan: a phase I studyG L Phillips, B Meisenberg, D E Reece, et al.
Bone Marrow Transplantation|February 10, 2004
Activity of single-agent melphalan 220-300 mg/m2 with amifostine cytoprotection and autologous hematopoietic stem cell support in non-Hodgkin and Hodgkin lymphomaG L Phillips, B R Meisenberg, D E Reece, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Pharmacotherapy|July 25, 2000
Adverse events associated with chemotherapy for common cancersV R Adams
Journal of the American Pharmaceutical Association (Washington, D.C. : 1996)|October 26, 1999
Oprelvekin (Neumega), first platelet growth factor for thrombocytopeniaV R Adams, T Brenner
The Annals of Pharmacotherapy|December 1, 1995
Granisetron: the second serotonin-receptor antagonistV R Adams, A W Valley
Journal of the American Pharmaceutical Association (Washington, D.C. : 1996)|February 28, 1998
Cancer vaccines (1)P A Hallin, V R Adams
Journal of the American Pharmaceutical Association (Washington, D.C. : 1996)|January 13, 1998
Cancer vaccines. Part 2P A Hallin, V R Adams
The Annals of Pharmacotherapy|October 31, 2000
Computerized system for outcomes-based antiemetic therapy in childrenM T Holdsworth, V R Adams, D W Raisch, et al.
The Annals of Pharmacotherapy|January 1, 1995
Continuous midazolam infusion for the management of morphine-induced myoclonusM T Holdsworth, V R Adams, C M Chavez, et al.
Transplantation|February 11, 1998
Delayed graft function after renal transplantationW W Pfaff, R J Howard, P R Patton, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 19, 2004
Amifostine and autologous hematopoietic stem cell support of escalating-dose melphalan: a phase I studyG L Phillips, B Meisenberg, D E Reece, et al.
Bone Marrow Transplantation|February 10, 2004
Activity of single-agent melphalan 220-300 mg/m2 with amifostine cytoprotection and autologous hematopoietic stem cell support in non-Hodgkin and Hodgkin lymphomaG L Phillips, B R Meisenberg, D E Reece, et al.
Pageof 1